- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Spectral Medical announced the retirement of their executive vice president and chief financial officer, Tony Businskas, will be retiring at the start of 2018.
Spectral Medical (TSX:EDT) announced the retirement of their executive vice president and chief financial officer, Tony Businskas, will be retiring at the start of 2018.
As quoted in the press release:
Tony joined Spectral in 2005 from his role as a senior VP and CFO for MDS Pharma Services and quickly became an important and key member of the senior management team. Tony’s oversight of the Company’s financial reporting and controls, as well as his leadership and guidance through many years of successful financings, third party license negotiations and operations, has been invaluable in setting the Company up for continued success.
Dr. Paul Walker, the Chief Executive Officer of Spectral commented, “Tony has been a tremendous asset to the Spectral vision of creating a unique theranostic company. His relentless hard work has helped pave the way for our ongoing efforts for FDA approval of a targeted treatment for patients with septic shock. The Board of Directors joins me in sincerely thanking Tony for his many years of dedicated work and wish him the best for a well-deserved retirement.”
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.